messag report earn morn see press releas
pharmaceut segment remain drive forc behind compani growth
oper sale growth exclud acquisit divestitur first
quarter vs driven growth pharma yoy us ou
consum yoy medic devic yoy compani host
investor event may focu event consum medic
devic busi segment strategi babi restag plan
later year
experienc continu sale momentum driven primarili pharma growth
compani record total revenu yoy net earn
quarter dilut ep exclud after-tax intang amort expens
special item adjust net earn came yoy adjust ep
yoy oper basi adjust dilut ep also increas
addit accord compani tax reform creat opportun
invest capit invest
focu remain pharma
growth jnj pharmaceut segment drive manag upbeat outlook
manag note call compani key pharma product seen
doubl digit growth world-wide pharmaceut sale billion
repres yoy growth yoy oper increas posit fx
impact exclud impact acquisit divestitur ww sale increas
yoy ou growth jnj pharma busi driven
strong perform key product recent launch sever new product
immunolog grew approxim stelara crohn diseas continu
experi strong growth well strong growth pharma off-set
biosimilar eros remicad gener competit face procrit tracleer
segment led oncolog portfolio grew global
darzalex continu perform global growth yoy continu market
growth strong launch uptak one prior line indic darzalex result
share gain outsid darzalex experienc increas penetr
countri commerci avail seen strong growth
asia-pacif region due approv japan last novemb manag expect
darzalex experi strong growth first-lin approv current on-going
phase studi subcu formul expect file imbruvica also
continu gain market share across line therapi larg driven
share chronic lymphocyt leukemia cll note manag estim cll
market grown approxim
zytiga grew strong growth driven recent fda approv
addit indic zytiga combin prednison treatment
metastat high-risk castrat sensit prostat cancer base data phase
latitud trial approv result market share expans zytiga result
zytiga strong growth manag continu expect zytiga affect
gener competit compani addit expand presenc prostat
cancer approv erleada next-gener androgen receptor
inhibitor treatment non-metastat castration-resist prostat cancer patient
compani previous file eu approv februari
page analyst certif import disclosur
increas sale guidanc reflect oper growth
year-over-year growth exclud acquisit divestitur
manag note morn earn call increas sale guidanc
driven strong growth segment adjust earn guidanc
reiter ep repres yoy growth
manag reiter call expect earn continu grow
acceler pace comparison total revenu constant currenc basi net interest
expens expect incom roughli rang
 tax rate full year reiter
addit oper margin expect see approxim bp increas
increas manag previou guidanc basi point
increas manag bullish expect oper profit driven lower cog
due mix product sold well slower increas rate sm relat
rate revenu growth particularli pronounc segment
made adjust model base earn result updat guidanc
manag commentari earn call revenu estim increas
forecast strong pharmaceut segment growth believ
pharmaceut segment growth continu experi growth due manag
commentari call well new product approv product launch expect
increas oper margin base manag guidanc
basi point increas yoy previous bp adjust ep
estim increas ep estim
increas respect
valuat risk
valuat share current trade ep believ trade
time forward earn base histor multipl compani
earn therefor maintain neutral rate ep estim increas
ep estim increas respect
upsid risk neutral rate thesi includ posit turn either md
consum busi favor commerci zytiga darzalex
imbruvica see import revenu driver upcom year
downsid risk includ biosimilar competit remicad jnj largest
product term gross sale stronger fx headwind anticip product
page analyst certif import disclosur
million except per-shar figur
good sold total
adjust non-gaap measur
reconcili one-time/non-gaap item
adjust incom tax
net impact non-gaap reconcili
impact adjust
compani report guggenheim secur llc estim
page analyst certif import disclosur
